Major trial finds apixaban reduces stroke risk in patients with device-detected atrial fibrillation

The widely available blood thinner apixaban substantially reduced stroke in at-risk patients with a type of atrial fibrillation only detectable by a pacemaker or other implanted cardiac electronic device, a global study has found.

Related Keywords

United States ,Canada ,Canadian ,American ,Bristol Myers Squibb ,Renato Lopes ,Stuart Connolly ,Jeff Healey ,Population Health Research Institute ,Canadian Institutes For Health Research ,Canadian Stroke Prevention Intervention Network ,Pfizer Alliance ,American Heart Association Scientific Sessions ,Duke Clinical Research Institute ,Hamilton Health Sciences ,Mcmaster University ,Stroke Foundation Of Canada ,New England Journal ,Hamilton Health ,Duke University School ,Canadian Institutes ,Health Research ,Bristol Myers Squibb Pfizer Alliance ,Stroke Foundation ,Advancing Clinical Trials ,Population Health Research ,Apixaban ,Atrial Fibrillation ,Flood ,Anticoagulant ,Bleeding ,Heart ,Medicine ,Pacemaker ,Research ,Stroke ,